---
schema_version: "secwatch.filing_event.v1"
accession: "0001827635-26-000028"
form_type: "8-K"
ticker: "MANE"
cik: "0001827635"
company_name: "Veradermics, Inc"
filed_at: "2026-08-11T12:15:58+00:00"
generated_at: "2026-08-11T12:20:16.722401+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Veradermics Q2 net loss $23.5M; positive Phase 2 female hair-loss data, cash $819.9M

## Summary
- Q2 2026 net loss $23.5M vs $15.6M YoY; R&D $18.6M (up $4.3M), G&A $10.9M (up $9.2M).
- Phase 2 Study 207: mean TAHC increase 22.7 (QD) and 23.3 (BID) hairs/cm² at Month 6; 88.9%/90.0% improved on AAIRS.
- Completed enrollment of Phase 2/3 Study 306 (556 female PHL patients); topline expected 1H27.
- Phase 3 Study 304 topline and 12-month Study 302 data both anticipated in 2H26.
- Cash $819.9M as of June 30, 2026; $472M raised in May 2026, funding into 2030.

## SEC filing metadata
- accession: 0001827635-26-000028
- form_type: 8-K
- ticker: MANE
- cik: 0001827635
- company_name: Veradermics, Inc
- filed_at: 2026-08-11T12:15:58+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827635/000182763526000028/0001827635-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827635/000182763526000028/mane-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001827635-26-000028
- JSON: https://secwatch.observer/filing/0001827635-26-000028.json
- Plain text: https://secwatch.observer/filing/0001827635-26-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.